Aluminium
- Generic Name
- Aluminium
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Al
- CAS Number
- 7429-90-5
- Unique Ingredient Identifier
- CPD4NFA903
- Background
A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
- Conditions
- HIV-1
- Interventions
- Biological: CH505 TF chTrimerOther: Sodium Chloride for InjectionBiological: 3M-052-AFBiological: Aluminum Hydroxide Suspension
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 30
- Registration Number
- NCT06680479
- Locations
- 🇺🇸
University of California, Los Angeles CARE Center CRS, Los Angeles, California, United States
🇺🇸UCSD Antiviral Research Center CRS, San Diego, California, United States
🇺🇸University of California, San Francisco HIV/AIDS CRS, San Francisco, California, United States
A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum
- Conditions
- HIV
- Interventions
- Biological: CD4BS CH505M5 Pr-NP1Biological: CH505TF chTrimerBiological: ACU-026-001-1 (labeled as empty LNP)Biological: 3M-052-AF (labeled as AP 60-702)Biological: Aluminum Hydroxide Suspension (Alum)
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-06-18
- Target Recruit Count
- 42
- Registration Number
- NCT06267872
- Locations
- 🇺🇸
Alabama CRS (Site ID: 31788), Birmingham, Alabama, United States
🇿🇦Setshaba Research Centre CRS (Site ID: 31829), Soshanguve, Gauteng, South Africa
🇿🇦Isipingo CRS (Site ID: 31635), Isipingo, Kwa Zulu Natal, South Africa
Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-10-02
- Target Recruit Count
- 52
- Registration Number
- NCT04915768
- Locations
- 🇺🇸
Vanderbilt Vaccine (VV) CRS, Nashville, Tennessee, United States
🇺🇸The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
🇺🇸Brigham and Women's CRS, Boston, Massachusetts, United States
Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study
- Conditions
- SARS
- Interventions
- Drug: Aluminum hydroxide adjuvant (Alhydrogel®)Other: Phosphate buffered saline PlaceboBiological: Recombinant S protein SARS vaccine
- Locations
- 🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States
🇺🇸Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States
🇺🇸University of Iowa - Infectious Disease Clinic, Iowa City, Iowa, United States
A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 50
- Registration Number
- NCT00001012
- Locations
- 🇺🇸
Beth Israel Med Ctr / Peter Krueger Clinic, New York, New York, United States
🇺🇸Mem Sloan - Kettering Cancer Ctr, New York, New York, United States
🇺🇸Mount Sinai Med Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.